Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

BACKGROUND & AIMS Mutations in the mismatch repair genes cause hereditary nonpolyposis colorectal cancer (HNPCC) syndrome and convey high lifetime cancer risks for colorectal (CRC) and endometrial cancer. Currently, cancer risks for individuals with HNPCC are based on data from clinically ascertained families. The purpose of this study was to re-examine the penetrance in HNPCC using a comprehensive dataset from a geographically defined region. METHODS A combined dataset of 70 HNPCC families ascertained by traditional high-risk criteria and by molecular screening comprising 88 probands and 373 mutation-positive family members was used. Statistical methods were modified survival analysis techniques. RESULTS In mutation-positive relatives (excluding probands), the median age at diagnosis of CRC was 61.2 years (confidence interval [CI], 56.3-68.0 y). The lifetime risk for CRC was 68.7% (CI, 58.6%-78.9%) for men and 52.2% (CI, 37.6%-66.9%) for women. Considering only probands, the median age at diagnosis of CRC was 44.0 years (CI, 41.0-46.3 y). Median age of onset of EC was 62.0 years (CI, 55.9 y to an upper limit too high to calculate) with a lifetime cancer risk of 54% (CI, 41.9%-66.1%). CONCLUSIONS A markedly later age of onset for CRC at 61 y than previously reported (approximately 44 y) is suggested, resulting mainly from a more rigorous method of analysis in which all gene-positive individuals (both affected and unaffected with cancer) are considered. Lifetime cancer risks may be lower for CRC and endometrial cancer than presently assumed. If confirmed, these data suggest a need to alter counseling practices, and to consider HNPCC in older individuals than before.

[1]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[2]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[3]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[4]  A. Rustgi,et al.  The Hereditary Nonpolyposis Colorectal Cancer Syndrome: Genetics and Clinical Implications , 2003, Annals of Internal Medicine.

[5]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[6]  H. Lynch,et al.  Cancer risk in mismatch repair gene mutation carriers , 2004, Familial Cancer.

[7]  K. Kinzler,et al.  Founding mutations and Alu-mediated recombination in hereditary colon cancer , 1995, Nature Medicine.

[8]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[9]  J. Satagopan,et al.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Mecklin,et al.  Clinical features of colorectal carcinoma in cancer family syndrome , 1986, Diseases of the colon and rectum.

[11]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[12]  T. Smyrk,et al.  Hereditary nonpolyposis colorectal cancer--Lynch syndromes I and II. , 1988, Gastroenterology clinics of North America.

[13]  C. Begg On the use of familial aggregation in population-based case probands for calculating penetrance. , 2002, Journal of the National Cancer Institute.

[14]  F. Wright,et al.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C B Begg,et al.  The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Mecklin,et al.  Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer) , 1991, Cancer.

[18]  N. Zeps,et al.  Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  C. Bonaïti‐pellié,et al.  Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated , 2002, Journal of medical genetics.

[20]  M. Folstein,et al.  The use of life tables and survival analysis in testing genetic hypotheses, with an application to Alzheimer's disease. , 1983, American journal of epidemiology.

[21]  R. Fodde,et al.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. , 1996, Gastroenterology.

[22]  R. Elston,et al.  Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). I. Clinical description of resource , 1985, Cancer.

[23]  C. Boland,et al.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. , 1993, Gastroenterology.

[24]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[25]  H. Lynch,et al.  Cumulative incidence of colorectal and extracolonic cancers in mlh1 and msh2 mutation carriers of hereditary nonpolyposis colorectal cancer , 2007, Journal of Gastrointestinal Surgery.

[26]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[27]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[28]  J. Mecklin,et al.  Hereditary non-polyposis colorectal cancer , 1991, The Lancet.

[29]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[30]  S. Olschwang,et al.  Cancer risk in 348 French MSH2 or MLH1 gene carriers , 2003, Journal of medical genetics.

[31]  W. Grady,et al.  Diagnosis and management of hereditary non-polyposis colon cancer. , 2003, Gastrointestinal endoscopy.

[32]  P. Peltomäki,et al.  Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations , 2004, Familial Cancer.

[33]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[34]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[35]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[36]  L. Cone,et al.  An update on the acquired immunodeficiency syndrome (AIDS) , 1986, Diseases of the colon and rectum.